In late December 2019, cases of unexplained pneumonia in China, Wuhan were reported (1). On January 21, 2020, the World Health Organization (WHO) provisionally designated the new coronavirus as coronavirus-2019 (COVID-19). Subsequently, the virus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is an enveloped, non-segmented virus containing a single-stranded, positive-sense RNA genome, belonging to the Coronaviridae family (2). Due to the pathogenesis of SARS-CoV-2 and the inflammatory response it triggers in the body, the virus may cause secondary complications that manifest in the long term. One of the potential long-term complications of SARS-CoV-2 could be carcinogenesis. Supporting this hypothesis, it has been estimated that about 15% of all human cancers worldwide are associated with viral infections. Both DNA and RNA viruses are capable of developing cancer in humans. In this regard, Epstein-Barr virus (3), human herpesvirus 8 (4), hepatitis B virus (5), and (6) are the four DNA viruses whose role in carcinogenesis has been indicated. Among the RNA viruses, Human T lymphotropic virus type 1 (7) and hepatitis C (8) viruses are known to contribute to human cancers. Given the importance of the issue and the worldwide distribution of SARS-CoV-2, the carcinogenic potential of this virus should be investigated. In this hypothetical article, we reviewed the possible mechanisms by which SARS-CoV-2 could be involved in cancer development.